- Home
- LOCO vs CLLS Comparison
LOCO vs CLLS Comparison
Compare LOCO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- CLLS
- Stock Information
- Founded
- LOCO 1980
- CLLS 1999
- Country
- LOCO United States
- CLLS France
- Employees
- LOCO N/A
- CLLS N/A
- Industry
- LOCO Restaurants
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- LOCO Consumer Discretionary
- CLLS Health Care
- Exchange
- LOCO Nasdaq
- CLLS Nasdaq
- Market Cap
- LOCO 323.7M
- CLLS 299.0M
- IPO Year
- LOCO 2014
- CLLS 2007
- Fundamental
- Price
- LOCO $10.53
- CLLS $3.28
- Analyst Decision
- LOCO Buy
- CLLS Buy
- Analyst Count
- LOCO 2
- CLLS 1
- Target Price
- LOCO $18.00
- CLLS $8.00
- AVG Volume (30 Days)
- LOCO 338.7K
- CLLS 171.0K
- Earning Date
- LOCO 10-30-2025
- CLLS 11-07-2025
- Dividend Yield
- LOCO N/A
- CLLS N/A
- EPS Growth
- LOCO 13.62
- CLLS N/A
- EPS
- LOCO 0.89
- CLLS N/A
- Revenue
- LOCO $480,815,000.00
- CLLS $63,438,000.00
- Revenue This Year
- LOCO $6.13
- CLLS N/A
- Revenue Next Year
- LOCO $1.56
- CLLS $66.76
- P/E Ratio
- LOCO $11.81
- CLLS N/A
- Revenue Growth
- LOCO 2.09
- CLLS 223.09
- 52 Week Low
- LOCO $8.29
- CLLS $1.10
- 52 Week High
- LOCO $13.24
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- LOCO 64.09
- CLLS 42.56
- Support Level
- LOCO $8.99
- CLLS $3.17
- Resistance Level
- LOCO $10.83
- CLLS $3.79
- Average True Range (ATR)
- LOCO 0.38
- CLLS 0.33
- MACD
- LOCO 0.14
- CLLS -0.10
- Stochastic Oscillator
- LOCO 83.74
- CLLS 4.94
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.